Add a bookmark to get started

14 January 20202 minute read

DLA Piper advises Osceola Capital in its acquisition of Healthcents

DLA Piper is pleased to announce that the firm represented Osceola Capital, a middle-market private equity firm focused on services businesses, in its acquisition of Healthcents, Inc., a leading provider of medical reimbursement and related services.

Founded in 1994, Healthcents consults small and medium healthcare providers across the United States on payor portfolio and growth strategies by strengthening or entirely outsourcing traditional managed care departments.

"We were pleased to advise our client Osceola Capital on this transaction, drawing on our deep experience in healthcare private equity to help Osceola achieve its goals," said Brian Gordon, who led DLA Piper's deal team.

In addition to Gordon (Atlanta), the DLA Piper team representing Osceola Capital included partners Anna Spencer, Kevin Gooch (both of Atlanta), Julia Kovacs (Washington, DC), Stacy Paz (Silicon Valley) and William Bartow (Philadelphia); attorney Bradley Verona (Atlanta); and associates Julie Franki, James Rusert (both of Atlanta), Emily Maus (Washington, DC), Mary Claire Blythe (Baltimore), Nika Antonikova (San Diego), Priya Narahari (Philadelphia) and Zachary Nolan (Silicon Valley).

With more than 100 US-based lawyers and more than 130 internationally-based lawyers, DLA Piper's Private Equity practice represents private equity funds, equity sponsors, corporations, strategic investors, fund principals, management teams, institutional investors, financing sources and portfolio companies. In 2018, PitchBook recognized DLA Piper as the second most active private equity law firm in the US and globally by deal volume.

The firm's global Healthcare sector consists of a multidisciplinary legal team with niche experience in health-related business and legal issues. The team regularly works with corporations and financial institutions, private investors, private equity groups, venture capital funds, institutional investors and portfolio companies in all types of healthcare transactions.